WASHINGTON — The Biden administration on Tuesday moved to axe a Trump-era policy that would have targeted federal drug discounts for clinics serving low-income people.
While several other controversial Trump drug pricing policies on importation, international reference pricing, and drug rebates remain in limbo, this is the second time that HHS Secretary Xavier Becerra has sided with providers at the expense of drug makers on contentious policy related to the federal 340B drug discount program.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
